National Healthcare Agreement: PI 10–Prevalence of Type 2 diabetes, 2021
Identifying and definitional attributes
|Metadata item type:||Indicator|
|Indicator type:||Progress measure|
|Short name:||PI 10–Prevalence of Type 2 diabetes, 2021|
|Registration status:||Health, Standard 03/07/2020|
The proportion of people who have Type 2 diabetes.
|Indicator set:||National Healthcare Agreement (2021) Health, Standardisation pending 03/08/2020|
|Outcome area:||Prevention Health, Standard 07/07/2010|
Collection and usage attributes
The National Health Measures Survey component of the 2011–13 Australian Health Survey (ABS cat. no. 4364.0.55.005) included a fasting plasma glucose test.
A respondent to the survey is considered to have known diabetes if they had ever been told by a doctor or nurse that they have Type 2 diabetes and:
A respondent to the survey is considered to have newly diagnosed diabetes if they reported no prior diagnosis of diabetes, but had a fasting plasma glucose value greater than or equal to 7.0 mmol/L.
Excludes persons who did not fast for 8 hours or more prior to their blood test.
Excludes women with gestational diabetes.
The data are reported for two age ranges:
Rates are directly age-standardised to the 2001 Australian population.
Analysis by remoteness and Socio-Economic Indexes for Areas (SEIFA) Index of Relative Socio-Economic Disadvantage (IRSD) is based on usual residence of the person (based on data availability).
Presented as a percentage.
95% confidence intervals and relative standard errors calculated for rates.
Note: The type of diabetes for newly diagnosed cases cannot be determined from a fasting plasma glucose or HbA1c test alone. However, it is assumed that the vast majority of newly diagnosed cases would be Type 2.
100 x (Numerator ÷ Denominator)
Number of persons aged 18 and over with known diabetes (Type 2) or newly diagnosed diabetes as determined by a fasting plasma glucose test.
For the supplementary measure: number of persons aged 25 and over with known diabetes (Type 2) or newly diagnosed diabetes as determined by a fasting plasma glucose test.
|Numerator data elements:|
Population aged 18 and over.
For the supplementary measure: population aged 25 and over.
|Denominator data elements:|
State and territory, by:
Nationally, by (all not reported this cycle):
Some disaggregation may result in numbers too small for publication.
|Disaggregation data elements:|
Most recent data available for 2021 National Healthcare Agreement performance reporting: 2011-12 (total population, non-Indigenous: AHS); 2012–13 (Indigenous only: AATSIHS).
NO NEW DATA FOR 2021 REPORTING.
|Unit of measure:||Person|
Data source attributes
National Healthcare Agreement
|Organisation responsible for providing data:|
Australian Bureau of Statistics
|Further data development / collection required:|
Specification: Final, the measure meets the intention of the indicator.
Source and reference attributes
Australian Bureau of Statistics
Australian Bureau of Statistics (ABS) 2013. Australian Health Survey: Biomedical Results for Chronic Diseases, 2011–12, ABS cat. no. 4364.0.55.005. Canberra: ABS. Viewed 11 May 2020, https://www.abs.gov.au/AUSSTATS/abs@.nsf/Lookup/4364.0.55.005
|Related metadata references:|
See also Australian Health Performance Framework: PI 3.1.7–Prevalence of type 2 diabetes, 2019 Health, Standard 09/04/2020
See also National Healthcare Agreement: PB c–Better health: reduce the age-adjusted prevalence rate for Type 2 diabetes to 2000 levels (equivalent to a national prevalence rate (for 25 years and over) of 7.1 per cent) by 2023, 2021 Health, Standard 03/07/2020
Supersedes National Healthcare Agreement: PI 10–Prevalence of Type 2 diabetes, 2020 Health, Standard 13/03/2020
See also National Healthcare Agreement: PI 15–Effective management of diabetes, 2021 Health, Standard 03/07/2020